British drug maker Glaxosmithkline Plc said Thursday that it will pay privately held drug developer Inc. 58.3 million Lrb Euro16 .3 million Rrb in cash and financing to begin a collaboration to develop new medicines to treat inflammatory diseases.
Glaxosmithkline to develop treatments.